Iron Infusion Into a Vein Compared to Iron Tablet Taken by Mouth for Treating Iron Deficiency Anemia in Pregnancy (IVON)

Launched by UNIVERSITY OF LAGOS, NIGERIA · Jul 18, 2021

Keywords

ClinConnect Summary

1.0 INTRODUCTION Anemia in pregnancy (AIP) remains a critical global health problem especially in low- and middle-income countries (LMICs), affecting 46% of pregnant women in Africa and 49% in Asia. AIP is defined as a venous blood hemoglobin concentration of \<11 g/dl in a pregnant woman. Iron deficiency anemia (IDA) is the commonest cause of AIP, accounting for 50-75% of AIP. Antenatal maternal anemia has significant implications on both maternal and neonatal outcomes, including maternal mortality from hemorrhage and morbidity from infections, and neonatal low birth weight and prematurity...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Pregnant women aged 15 to 49 years old between 20\*- and 32\*\*-weeks' gestational age.
• • Baseline (enrollment) laboratory-confirmed moderate or severe anemia (Hb \< 10g/dl).
• Exclusion Criteria:
• • Medically-confirmed significant bleeding, major surgery or received blood transfusion within the last 3 months.
• • Severe symptomatic anemia needing urgent correction with blood transfusion.
• • Anemia of other cause besides IDA e.g., Sickle cell anemia.
• • Clinically-confirmed malabsorption syndrome.
• • Hypersensitivity to any form of iron treatment.
• • History of any immune related illness e.g., SLE, Rheumatoid arthritis.
• • Preexisting maternal depression or other psychiatric illness.
• • Severe allergic reactions such as severe asthma.
• • History of severe drug allergy.